Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4092168 | 1.00 | DGAT1 (0.43) | DGAT1HDAC1HDAC6KDM4EGLA | |
| SCHEMBL13362737 | 0.82 | DGAT1 (0.58) | DGAT1HDAC1HDAC6KDM4EGLA | |
| SCHEMBL1571259 | 0.82 | KDM4E (0.50) | DGAT1HDAC1HDAC6KDM4EGLA | |
| Bromide SCHEMBL2372508 | 0.81 | KDM4E (0.48) | DGAT1HDAC1HDAC6KDM4EGLA | |
| SCHEMBL2061038 | 0.80 | HDAC1 (0.44) | DGAT1HDAC1HDAC6ALDH1A1KMT2A | |
| SCHEMBL31064366 | 0.80 | KDM4E (0.46) | DGAT1HDAC1HDAC6KDM4EGLA | |
| SCHEMBL31318246 | 0.80 | ALDH1A1 (0.47) | DGAT1HDAC1HDAC6KDM4EGLA | |
| SCHEMBL16411013 | 0.80 | KDM4E (0.46) | DGAT1HDAC1HDAC6KDM4EGLA | |
| SCHEMBL20392559 | 0.80 | DGAT1 (0.40) | DGAT1HDAC1HDAC6KDM4EGLA | |
| SCHEMBL16461500 | 0.80 | CES2 (0.42) | DGAT1PTGDR2MAOBMAOACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747261-A1 | AMINOPYRIMIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS | Accutar Biotechnology Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12338248-B2 | Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors | ACCUTAR BIOTECHNOLOGY INC. (US) | 2025-06-24 | — | — | US | disclosed |
| EP-4562000-A1 | AMINOHETEROARYL KINASE INHIBITORS | Allorion Therapeutics Inc (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-119630652-A | Amino heteroaryl kinase inhibitors | 安锐生物医药公司 | 2025-03-14 | — | — | CN | disclosed |
| WO-2025038420-A1 | KAPPA OPIOID RECEPTOR ANTAGONIST AND METHODS AND PRODUCTS RELATED THERETO | Neumora Therapeutics, Inc. (US) | 2025-02-20 | — | — | WO | disclosed |
| WO-2025024388-A1 | AMINOPYRIMIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| CN-112469720-B | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | 艾科思莱德制药公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2024022487-A1 | AMINOHETEROARYL KINASE INHIBITORS | Allorion Therapeutics Inc (US) | 2024-02-01 | — | — | WO | disclosed |
| CN-110655509-B | 2-aminopyrimidine derivatives, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2023-01-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338248-B2 | Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors | CDK6, CDK2, CDK8 | DGAT1 3248/4885HDAC1 581/4885HDAC6 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.